Abstract
We report a fatal case of native valve endocarditis due to Mycobacterium abscessus in a hemodialysis patient. The diagnosis was based on culture isolation of acid-fast bacilli from peripheral blood and a permanent catheter tip, and their identification as M abscessus by a reverse hybridization-based assay and direct DNA sequencing of the 16S-23S internal transcribed spacer region. Rapid diagnosis and combination therapy are essential to minimize mortality due to this pathogen. Although combination therapy was started with clarithromycin and tigecycline, the patient refused to take clarithromycin due to severe abdominal pain. The patient became afebrile after therapy with tigecycline alone although bacteremia persisted. He was discharged against medical advice and readmitted three months later for persistent fever. His blood cultures again yielded M abscessus and a transesophageal echocardiogram showed two mobile vegetations. The patient was noncompliant with therapy and died due to cardiac arrest and multiorgan failure. This report shows that M abscessus should also be considered in the differential diagnosis of infective endocarditis in hemodialysis patients.
Clinical syndromes caused by nontuberculous mycobacteria (NTM) have gained attention since the 1980s due to the increase in disseminated infections in association with the human immunodeficiency virus (HIV) epidemic.1,2 Nontuberculous mycobacterial disease occurs infrequently in immunocompetent individuals.2 Despite their ubiquitous presence in soil and water, the occurrence of various NTM species varies greatly by geographic region. Based on their growth rates, NTM have been classified into slowly growing or rapidly growing mycobacteria. Rapidly growing mycobacteria grow within seven days on solid media.3 More than 70% of rapidly growing mycobacterial infections are attributed to Mycobacterium abscessus, Mycobacterium fortuitum, and Mycobacterium chelonae.4 Species-specific identification is critical for treatment selection and prognosis; however, conventional methods are time-consuming and do not reliably differentiate some species such as M abscessus and M chelonae.3 We report a rare case of native valve endocarditis in a dialysis patient with no previous history of abnormal valves or heart murmur. Application of molecular methods identified the etiological agent as M abscessus.
CASE
A 54-year-old Kuwaiti man was admitted to Al-Amiri (a major tertiary care) hospital in May 2007 with a 4-week history of progressive general weakness, fever, and weight loss. The underlying conditions included chronic liver disease secondary to chronic hepatitis C and alcoholic cirrhosis, end-stage renal disease requiring hemodialysis for two years, and chronic obstructive pulmonary disease. His vital signs were as follows: temperature 38.1°C, pulse 90/min, blood pressure 140/70 mm Hg and respiratory rate 20/min. Also noted were an ejection systolic murmur (grade 2/6) over the aortic area and a pansystolic murmur at the apex radiating to the axilla. There were no skin lesions or other abnormalities.
Laboratory investigations revealed a peripheral WBC count of 4.7×10 9 /L (83% polymorphs), hemoglobin at 9.1 g/dL, erythrocyte sedimentation rate of 80 mm/h, and a platelet count of 107×10 9 /L. Chest radiography and urine analysis results were normal, and tests for antibodies to hepatitis B and HIV, a skin test for tuberculosis and tumor markers for abdominal malignancy were negative. Urea (20.4 mmol/L) and creatinine (721 μmol/L) levels were elevated; electrolyte and cardiac enzyme levels and liver function tests were normal. Blood was drawn on five separate days spanning 9 days through vein puncture (peripheral blood), perm-catheter and peripheral catheter. Cultures of these blood samples and culture of the perm-catheter tip yielded gram-positive beaded bacilli within 60-110 hours in a BACTEC 9240 system (Becton Dickenson). Two types of colonies (smooth and rough morphology) grew on chocolate agar, both showing gram-positive beaded bacilli. Ziehl-Neelsen stain of all cultured organisms showed acid-fast bacilli, suggesting mycobacterial infection.
DNA from the isolates was prepared by the boiling method and treated with Chelex-100 to remove PCR inhibitors, as described in detail previously.5 Specific amplification of an rpoB-derived 136 bp fragment in a multiplex PCR carried out as described previously,6 identified the isolates as NTM. A commercial reverse hybridization-based (INNO-LiPA Mycobacteria v2, Innogenetics, Belgium) assay was used, as described in detail previously,7 which identified all the cultured isolates as being M abscessus (Figure 1). The results were confirmed by DNA sequencing of species-specific 16S-23S internal transcribed spacer (ITS) region for two blood culture isolates and for the isolate grown from the perm-catheter tip. The ITS region was amplified as described previously,7 except that panmycobacterial primers (MYCF, 5’-GATTGGGACGAAGTCGTAACAAG-3’ and MYCR, 5’-CTCGGTTGACAGCTCCCCGAG-3’) derived from 16S and 23S rRNA genes were used. The amplified fragments were purified and both strands were sequenced by using amplification primers and a cycle DNA sequencing kit (DTCS CEQ 2000, Beckman-Coulter) as described previously.7,8 The DNA sequences of the 16S-23S ITS region from all the three isolates were completely identical (EMBL accession nos. FM955484-FM955486) and showed 100% identity with the corresponding sequences from several M abscessus strains in BLAST (http://www.ncbi.nlm.nih.gov/BLAST/Blast.cgi) searches, which confirmed their identity as M abscessus. The organism was susceptible to amikacin, clarithromycin, imipenem, and tigecycline, but resistant to streptomycin, isoniazid, rifampicin, ethambutol, and pyrazinamide.
Following specific diagnosis, the perm-catheter was removed and a femoral catheter was fixed for dialysis. Treatment was started with intravenous clarithromycin (500 mg twice daily) and tigecycline (50 mg twice daily), but the patient refused to take clarithromycin after two days due to severe abdominal pain. Despite monodrug therapy with tigecycline for two weeks, the patient became afebrile and although bacteremia persisted and follow-up blood cultures again yielded M abscessus, the patient was discharged against medical advice. He was readmitted three months later and two sets of blood cultures again yielded M abscessus (Figure 1) with the same susceptibility profile as recorded earlier. Transthoracic echocardiography revealed aortic sclerosis, concentric left ventricular hypertrophy (LVH), and thick mitral annular calcification with a high suspicion of vegetation on the anterior mitral valve leaflet (AMVL). Transesophageal echocardiography showed a grossly distorted mitral valve (MV), moderate mitral regurgitation, and two mobile echodense vegetations of 0.6×0.6 cm on the atrial side of AMVL and the base of the aortic valve. Based on blood cultures and transesophageal echocardiography, a clinical diagnosis was made of native valve endocarditis due to M abscessus. Treatment with clarithromycin and tigecycline was restarted, but the patient was noncompliant. Three weeks later, transesophageal echocardiography again showed significant increase in the size of the vegetations attached to the AMVL. Abdominal sonography revealed an enlarged liver, moderate splenomegaly, and free fluid in the peritoneal cavity. The ECG showed loss of the R wave and a tall peaked T-wave. The patient died due to cardiac arrest five weeks after the second hospitalization as a result of multi-organ failure.
DISCUSSION
Mycobacterium abscessus is widespread in the environment and has been documented as a source of nosocomial infection in immunocompromised patients. The organism is capable of colonizing the respiratory tract and causes pulmonary disease in certain high-risk groups such as white females older than 60 years of age and patients with cystic fibrosis or prior pulmonary mycobacterial infection, particularly tuberculosis.4,9 Although M abscessus infections can occur in both immunocompetent and immunocompromised hosts, immune status and underlying comorbidities contribute to the disease severity, and disseminated infections are typically seen in patients with impaired immunity.4,10 Mycobacterium abscessus has the ability to form biofilms and to grow even in distilled water. Due to its occurrence in municipal water supply systems as a result of its resistance to common disinfectants, M abscessus may also cause cutaneous infections that usually resolve themselves but may occasionally also require medical or surgical treatment.4,10 Mycobacterium abscessus and its close relatives have also been found in water used in reprocessing hemodialyzers and have been associated with bacteremia and disseminated disease in hemodialysis patients.11,12 In an outbreak involving 27 hemodialysis patients, the source of infection was traced to exposure to processed hemodialyzers that contained viable, rapidly growing mycobacteria; 25 out of 27 patients were infected with M abscessus.12 Although not investigated, it is probable that the source of infection in the present case also involved the use of a hemodialyzer as skin lesions were absent and pulmonary involvement was not apparent.
Rapid diagnosis and prolonged combination therapy are mandatory for proper treatment and to minimize mortality as M abscessus is inherently resistant to multiple antibiotics.2,4 Species-specific identification of M abscessus by conventional methods is time-consuming and may not be reliable and recently developed molecular methods have provided more accurate identification. The present case was also identified by the application of molecular methods.
M abscessus strains isolated from patients with pulmonary involvement invariably show in vitro resistance to antituberculous drugs. Although treatment of such patients with standard antituberculous drug therapy results in considerable clinical and radiological improvement, M abscessus-specific treatment is required for complete resolution of the infection.13 Typically, antibiotics with maximum in vitro activity against M abscessus isolates include amikacin, clarithromycin, tigecycline, and cefoxitin. To a lesser extent, linezolid and imipenem are also effective against nearly 50% of clinical M abscessus isolates. However, in vitro drug susceptibility patterns do not always correlate with clinical response and measurements of minimum inhibitory concentrations of antibiotics do not always predict their therapeutic effects.4 Successful management of patients with disseminated infections usually involves prolonged combination therapy (>6 months) with a macrolide (clarithromycin) or amikacin plus imipenem, cefoxitin, or tigecycline.4,10 Combination therapy with clarithromycin and tigecycline was also started in our case, but the patient refused to take clarithromycin due to severe abdominal pain. Although removal of catheters and treatment with tigecycline reduced the bacterial load, bacteremia persisted, most likely due to the shorter duration of monodrug therapy that was insufficient to completely resolve the deep-seated infection (heart valves). Di Pentima et al14 diagnosed a case of sepsis (and presumed endocarditis) due to M abscessus in a very low birth weight neonate by high performance liquid chromatography analysis of fatty acids and successfully managed it by combination therapy. Although amikacin and cefoxitin have exhibited intermediate in vitro activity against M abscessus, prolonged combination therapy with these two agents has been reported to completely resolve the infection.14 Although noncompliance with the therapy regimen most likely resulted in a fatal outcome for our patient, endocarditis caused by M abscessus generally has very poor prognosis despite combination antimicrobial therapy as only two of the ten documented cases described in the literature have survived after treatment.15 In conclusion, M abscessus should be considered in the differential diagnosis of endocarditis in hemodialysis patients, and molecular methods are useful for its rapid and specific identification.
Acknowledgments
We thank Prof. Kamel for providing the patient details. Supported in part by KURA grant MI02/04.
REFERENCES
- 1.Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis. 1979;119:107–59. doi: 10.1164/arrd.1979.119.1.107. [DOI] [PubMed] [Google Scholar]
- 2.Wagner D, Young LS. Nontuberculous mycobacterial infections: A clinical review. Infection. 2004;32:257–70. doi: 10.1007/s15010-004-4001-4. [DOI] [PubMed] [Google Scholar]
- 3.Brown-Elliott BA, Wallace RJ., Jr Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev. 2002;15:716–46. doi: 10.1128/CMR.15.4.716-746.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Colombo RE, Olivier KN. Diagnosis and treatment of infections caused by rapidly growing mycobacteria. Semin Respir Crit Care Med. 2008;29:577–88. doi: 10.1055/s-0028-1085709. [DOI] [PubMed] [Google Scholar]
- 5.Ahmad S, Mokaddas E, Jaber AA. Rapid detection of ethambutol-resistant Mycobacterium tuberculosis strains by PCR-RFLP targeting embB codons 306 and 497 and iniA codon 501 mutations. Mol Cell Probes. 2004;18:299–306. doi: 10.1016/j.mcp.2004.04.001. [DOI] [PubMed] [Google Scholar]
- 6.Mokaddas E, Ahmad S. Development and evaluation of a multiplex PCR for rapid detection and differentiation of Mycobacterium tuberculosis complex members from non-tuberculous mycobacteria. Jpn J Infect Dis. 2007;60:140–4. [PubMed] [Google Scholar]
- 7.Mokaddas E, Ahmad S. Species spectrum of non-tuberculous mycobacteria isolated from clinical specimens in Kuwait. Curr Microbiol. 2008;56:413–7. doi: 10.1007/s00284-008-9102-3. [DOI] [PubMed] [Google Scholar]
- 8.Ahmad S, Mokaddas E. The occurrence of rare rpoB mutations in rifampicin-resistant Mycobacterium tuberculosis isolates from Kuwait. Int J Antimicrob Agents. 2005;26:205–12. doi: 10.1016/j.ijantimicag.2005.06.009. [DOI] [PubMed] [Google Scholar]
- 9.Daley CL, Griffith DE. Pulmonary disease caused by rapidly growing mycobacteria. Clin Chest Med. 2002;23:623–32. doi: 10.1016/s0272-5231(02)00021-7. [DOI] [PubMed] [Google Scholar]
- 10.De Groote MA, Huitt G. Infections due to rapidly growing mycobacteria. Clin Infect Dis. 2006;42:1756–63. doi: 10.1086/504381. [DOI] [PubMed] [Google Scholar]
- 11.Carson LA, Bland LA, Cusick LB, Favero MS, Bolan GA, Reingold AL, et al. Prevalence of nontuberculous mycobacteria in water supplies of hemodialysis centers. Appl Environ Microbiol. 1988;54:3122–5. doi: 10.1128/aem.54.12.3122-3125.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Bolan G, Reingold AL, Carson LA, Silcox VA, Woodley CL, Hayes PS, et al. Infections with Mycobacterium chelonae in patients receiving dialysis and using processed hemodialyzers. J Infect Dis. 1985;152:1013–9. doi: 10.1093/infdis/152.5.1013. [DOI] [PubMed] [Google Scholar]
- 13.Nishizawa Y, Fujimura M, Tagami A, Abo M, Honjyo C, Yasui M, et al. Two cases of pulmonary infection by MycobacteriuM abscessus in which drug susceptibility testing results conflicted with clinical course. Nihon Kokyuki Gakkai Zasshi. 2005;43:241–6. [PubMed] [Google Scholar]
- 14.Di Pentima MC, Doyle R, Locke R, Tuttle D. Late-onset MycobacteriuM abscessus sepsis in a very low birthweight premature infant: Diagnostic and therapeutic challenges. Am J Perinatol. 2004;21:365–8. doi: 10.1055/s-2004-831885. [DOI] [PubMed] [Google Scholar]
- 15.Tsai WC, Hsieh HC, Su HM, Lu PL, Lin TH, Sheu SH, et al. MycobacteriuM abscessus endocarditis: A case report and literature review. Kaohsiung J Med Sci. 2008;24:481–6. doi: 10.1016/S1607-551X(09)70005-1. [DOI] [PubMed] [Google Scholar]